Biohaven is a pre-revenue clinical-stage biotech with a broad late-stage pipeline, but its aggressive R&D investment has produced persistent quarterly net losses averaging over $150M and a deteriorating balance sheet. The company's equity has collapsed from $4...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.91-19.6% vs -$0.76 | — vs $490,492 |
Q2 2026 May 4, 2026 | -$0.88-2.3% vs -$0.86 | — vs $267,436 |
Q2 2026 Mar 2, 2026 | -$1.21+0.8% vs -$1.22 | — vs $400,000 |
Q4 2025 Nov 10, 2025 | -$1.64+14.1% vs -$1.91 | — vs $375,091 |
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead pivotal study in refractory focal epilepsy.
Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down more than 13% in premarket trading.
BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE: BHVN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,210,585 shares of the company's stock, valued at approximately $196,574,000. BlackRock Inc. owned approximately 8.77% of
Benchmark BHVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Biohaven Ltd. (BHVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.67 | $2.06B | -1.99 | — | — | -310.75% | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — | |
| $138.70 | $8.92B | -67.66 | -89.41% | 29.4% | 12.03% | — | |
| $0.56 | $10.83M | -0.17 | — | — | -187.45% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — |
Biohaven Ltd. (BHVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Biohaven Ltd. (BHVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 7, 2026·SEC
Jul 9, 2026·SEC
Get notified when BHVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Biohaven Ltd. (BHVN) stock FAQ — growth, dividends, profitability & financials explained
Biohaven Ltd. (BHVN) reported a net loss of $586.8M for fiscal year 2025.
Biohaven Ltd. (BHVN) has a return on equity (ROE) of -310.8%. Negative ROE indicates the company is unprofitable.
Biohaven Ltd. (BHVN) had negative free cash flow of $511.9M in fiscal year 2025, likely due to heavy capital investments.
